Evolve BioSystems, Inc. is the manufacturer of Evivo®, a proprietary groundbreaking probiotic proven to resolve Newborn Gut Deficiency, which studies have shown affects more than 90% of babies in the U.S. Evivo contains activated B. infantis EVC001 which restores key bacteria to the infant’s gut and guides critical development of infant’s digestive and immune system. Evivo works by favourably altering gut biochemistry to reduce potentially pathogenic bacteria by 80 per cent which in turn significantly reduces intestinal inflammation. Those pathogens and the inflammation which they cause are linked to a higher risk of both short- and long-term health issues including colic, diaper rash, eczema, asthma, allergies and even Type 1 Diabetes.
Martino Verga, CEO Sacco System
“We are impressed by the science that Evolve has done, and are excited to be within the European investors in Evolve. We believe in the mission of Evolve because our company CSL was the first company in Italy to study Lactic Acid Bacteria for human health.
One of Sacco System pillars is creative intelligence, with a focus on R&D and innovation. For this reason, we are proud to be a partner with Evolve, a company dedicated to developing the next generation of probiotics to improve life and wellbeing.
We strongly trust that there is always a probiotic that makes your life better”.
Sacco System and its reputation as a highly professional manufacturer of probiotics and other live biotherapeutics will support an investment that will help Evolve BioSystems, Inc in bringing Evivo® Baby Probiotic to Europe.
Tim Brown, CEO Evolve BioSystems, Inc.
“We are pleased to add Sacco to the growing list of investors in Evolve” said Tim Brown, CEO of Evolve BioSystems, “This investment from major Italian corporations signals the interest in Evolve’s proprietary product lines on a global Basis”.
Latest News
An important regulatory goal has been achieved with the conclusion reached by an independent expert panel for the self-affirmed GRAS (Generally Recognized as Safe) determination of our postbiotic CRL1505® HI.
El grupo acelera su estrategia de desarrollo en Sudamérica mediante una doble operación: la adquisición de una empresa uruguaya y la integración total de su filial brasileña. El grupo apunta
La leche es el recurso más valioso en la producción láctea.Solo es posible obtener productos de alta calidad a partir de leche de alta calidad, y en el panorama actual,
“Survivability of probiotic CA15 strain with and without fluconazole co-administration and its effect on gut microbiota and metabolome through SHIME® model” is the title of the study that has been
GRAS (Generally Recognised as Safe) is a designation by the US Food and Drug Administration (FDA) that indicates that a substance is considered safe based on expert consensus or a
Brisbane, 8 January 2025 Sacco System Australia, a leader in innovative probiotic and postbiotic solutions, is proud to announce that L. rhamnosus CRL 1505 HI (heat-inactivated) and Lactobacillus acidophilus LA1
Our commitment to sustainability: a review of an evolving journey We are proud to present the fifth edition of our Sustainability Report, an opportunity to reflect on the milestones achieved
Today in the presence of Luna Angelini Marinucci, from 2022 the Consul of Italy in Brisbane, with territorial jurisdiction over the State of Queensland and over the Northern Territory the
At Sacco System we have always put Sustainability at the very core of our activities and our commitment, which is why we are proud that our companies Caglificio Clerici, Sacco
Indianapolis, Ind., and Yeerongpilly, Queensland, Australia, March 13, 2024 – List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce
Sacco System is the international biotechnological company dedicated to the food, nutraceutical, and pharmaceutical industries, based on tradition, expertise, research, and innovation which sells and distributes its ingredients in more
We are proud to announce that Sacco System has made a significant donation in support of Action4Diabetes (A4D), mission—a UK-based charity committed to ensuring free access to crucial medical supplies,